Groundbreaking studies on leukemia treatments and the effects of GLP-1 inhibitors on VTE risk will be presented at the ASH 2024 Annual Meeting. Research shows that adding blinatumomab to chemotherapy boosts disease-free survival in pediatric B-ALL patients, while eltrombopag is effective in treating severe pediatric ITP. Additionally, GLP-1 agonists may reduce the risk of VTE in patients with type 2 diabetes. An interim analysis of a CLL trial demonstrates better outcomes with acalabrutinib and venetoclax compared to traditional chemotherapy. Overall, these studies show promising advancements in the treatment of various hematological disorders.
Source link
New Leukemia Txs, Fewer Blood Clots With GLP-1 Rxs
